A Detailed Look At What Patients Experience In Medullary Thyroid Cancer Clinical Study
- Conditions
- Medullary Thyroid Cancer
- Registration Number
- NCT06079723
- Lead Sponsor
- Power Life Sciences Inc.
- Brief Summary
Clinical studies, with a distinct emphasis on medullary thyroid cancer, play a pivotal role in evaluating the safety and effectiveness of novel treatments for this condition. These trials serve as essential tools to determine whether new medications surpass conventional therapies, providing substantial evidence to endorse their broader adoption.
The primary objective is to meticulously examine trial completion rates and voluntary withdrawals within this specific patient group. By actively participating in this observational study plays a critical role in pushing medical knowledge forward and advancing care for individuals suffering from the medullary thyroid cancer.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- NOT_YET_RECRUITING
- Sex
- All
- Target Recruitment
- 500
- Confirmed diagnosis of medullary thyroid cancer
- Aged ≥ 18 years old and ability to provide written informed consent obtained prior to participation in the study and any related procedures being performed
- No serious medical or psychiatric illness likely to interfere with participation in this clinical study.
- Is pregnant, breastfeeding or expecting to conceive within the projected duration of the study
- Any serious and/or unstable pre-existing medical disorders
- Patients who are currently receiving any other investigational drug.
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Number of medullary thyroid cancer patients who decide to enroll in a clinical trial 3 months Rate of medullary thyroid cancer patients who remain in clinical trial to trial completion 12 months
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
Power Life Sciences
🇺🇸San Francisco, California, United States